dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) Press Release dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026 Following the announced divestment of Animal Nutrition & Health (ANH) activities to CVC Capital Partners, the assets and liabilities of the divested business have been classified as Assets Held for Sale, and the financial results of the ANH activities have bee...
Dsm-firmenich announced the divestment of its ANH business to CVC, while it will retain a 20% minority stake for now. The deal value (EV of up to € 2.2bn for 100%; implying a c. 7x EV/normalized adjusted EBITDA multiple) is in line with recent market rumours although below our € 3bn forecast, while also other elements in the deal structure are a bit disappointing (price tag included €0.5bn earn-out, a loan & liquidity facility will be provided). Despite the lower than expected ANH deal metrics, ...
dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners Press Release dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, today announces it has entered into an agreement with CVC, a leading global private markets manager, to divest its Animal Nutrition & Health (“ANH”) business for an enterprise value of about €2.2 billion, which includes an earnout of up to €0.5 billion. dsm-firm...
Onward announces enrolment of the first participant in the Empower BP trial. The trial evaluates the ARC-IM system to address blood pressure instability in SCI patients. We note that Onward plans an interim analysis of the efficacy results in 2H26, which could accelerate timelines if fewer total patients are required. Short-term, we look forward to the FY25 results to gain a view on the ARC-EX commercial launch (9M25: 70 devices sold). We reiterate our € 8.9 TP and BUY rating.
ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM® System to address blood pressure instability after spinal cord injury (SCI)Blood pressure instability is a key unmet need after SCI, with a significant impact on cardiovascular health and quality of lifeThe first participant was enrolled at Craig Hospital in Denver, Colorado, USA EINDHOVEN, the Netherlands, Feb. 04, ...
Aedifica and Cofinimmo: Exchange offer to start tomorrow / Alfen: Preview: new year, new chances / BAM Group: Nice add-on in the Dutch housing market / dsm-firmenich: Givaudan 2026 guidance read-across / Heijmans: Preview: 2025F was the cat's meow / Melexis: 4Q25 preview, towards a cyclical recovery / TomTom: Preview 4Q25, look beyond 2026 / Van Lanschot Kempen: Small UK Fiduciary mandate, second of the month though
Onward announced the appointment of a new CFO, Ali Kiboro. Mr. Kiboro brings more than 25 years of financial experience to Onward. He joins Onward from AliveDx where he served as Chief Financial Officer, leading the company's financial strategy, capital markets activities, and operational transformation. Prior to AliveDx, Ali held a variety of senior financial leadership roles at Quest Diagnostics and General Motors. Ali holds an MBA in Finance from The Wharton School and a Bachelor of Science i...
ONWARD Medical Appoints Ali Kiboro as Chief Financial Officer EINDHOVEN, the Netherlands, Jan. 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, today announces the appointment of Ali Kiboro as Chief Financial Officer, effective January 2026. Ali brings more than 25 years of financial leadership experience across medical technology, tools and diagnostics, and general industry. He joins ONWARD Medical from AliveDx (formerly Quotient Lim...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.